Latest News and Press Releases

Major new study of over 7,000 living donor kidney transplant patients finds type of immunosuppressive therapy makes a difference to long-term outcome Basel, 3 June 2003 - The long-term chances of...

LONDON, May 12, 2003 (PRIMEZONE) -- Cordiant (NYSE:CDA) (LSE:CRI) announced on April 29, 2003 that it had received very preliminary approaches that could lead to an offer for the company. Since then,...

Incontinence treatment Enablex® purchased from Pfizer for up to USD 225 million51% of Idenix acquired, marking strategic expansion into antiviral medicinesBasel, 9 May 2003 - Having obtained...

LONDON, May 1, 2003 (PRIMEZONE) -- Cordiant Communications Group plc ("Cordiant") (NYSE:CDA) (LSE:CRI): -- Revenues down 11.3% on an underlying basis to 532.7 million Pounds (2001: 605.0...

LONDON, April 28, 2003 (PRIMEZONE) -- Cordiant Communications Group plc ("Cordiant") (NYSE:CDA) (LSE:CRI): Cordiant was notified on Friday, April 25, 2003 by one of its major clients, Allied Domecq...

Novel Novartis drug Certican has been shown to target many of the underlying causes of chronic allograft dysfunction or late graft lossBasel, 14 April - Certican (everolimus) is a novel,...

Licensing rights to two hepatitis B drugs, in addition to option rights to Idenix's attractive antiviral development portfolio, including its hepatitis C compound   Deal terms: USD 255 million...

LONDON, Feb. 20, 2003 (PRIMEZONE) -- Cordiant (NYSE:CDA): -- Cost savings of Pounds 45m exceed previous estimate of 27m pounds -- Focus on core Bates Group businesses, representing 85% of ...

Basel, 17 January 2003 - Novartis announced that its affiliate Novartis Pharma AG has signed a license agreement regarding a new multi dose dry powder inhaler Airmax(TM) developed by Ivax Corporation....

STOCKHOLM, Sweden, Oct. 11, 2002 (PRIMEZONE) -- Frango (Stockholm:FRANb): Third quarter - Earnings net of financial items for the third quarter amounted to SEK -5.6 million (-1.5m),...